Circulating Tumor DNA Analysis Associates with Progression- Free Survival ( PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/ R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

被引：1
|
作者：
Arnason, Jon E. [1 ]
Brouwer-Visser, Jurriaan [2 ]
Luminari, Stefano [3 ]
Tucker, David [4 ]
Kim, Tae Min [5 ]
Kim, Won Seog [6 ]
Magnano, Laura [7 ]
Sun, Dylan [2 ]
Cai, Jessica [2 ]
Cygan, Kamil [2 ]
Ambati, Srikanth [2 ]
Mohamed, Hesham [2 ]
Chaudhry, Aafia [2 ]
Jankovic, Vladimir [2 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Azienda Unita Sanit Locale IRCCS, Reggio Emilia, Italy
[4] Royal Cornwall Hosp, Truro, Cornwall, England
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea
[7] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179812
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
    Desai, Sanjal H.
    LaPlant, Betsy
    Macon, William R.
    King, Rebecca L.
    Wang, Yucai
    Inwards, David J.
    Micallef, Ivana
    Johnston, Patrick B.
    Porrata, Luis F.
    Ansell, Stephen M.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    BLOOD CANCER JOURNAL, 2021, 11 (09)
  • [32] A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma
    Hainsworth, John D.
    Arrowsmith, Edward R.
    McCleod, Michael
    Hsi, Eric D.
    Hamid, Oday
    Shi, Peipei
    Lin, Boris K.
    Fayad, Luis E.
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 216 - 218
  • [33] Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation
    Strati, Paolo
    Kim, Tae Min
    Danilov, Alexey, V
    Cheah, Chan Y.
    Yoon, Dok Hyun
    Jurczak, Wojciech
    Sharma, Shringi
    Yoon, Jeong Lim
    Arduini, Serena
    Saeh, Jamal
    Olsson, Richard F.
    Gregory, Gareth
    BLOOD, 2022, 140 : 6656 - 6658
  • [34] A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
    Lee, Seung Tae
    Pinto, Antonio
    Yimer, Habte
    Stevens, Don
    Posluszny, Wanda Knopinska
    Shum, Merrill Kingman
    Manda, Sudhir
    Leiba, Merav
    Canales, Miguel
    Kazmierczak, Maciej
    Jurczak, Wojciech
    Sureda, Anna
    Ma, Xi Wen
    Li, Kai
    Ingalls, Kimberly
    Arriola, Tara
    Arazy, Melina
    Shah, Jatin J.
    Shacham, Sharon
    Kauffman, Michael G.
    Nowakowski, Grzegorz S.
    BLOOD, 2021, 138
  • [35] Overall Survival with Tafasitamab plus Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study
    Nowakowski, Grzegorz S.
    Yoon, Dok Hyun
    Mondello, Patrizia
    Joffe, Erel
    Peters, Anthea
    Fleury, Isabelle
    Greil, Richard
    Ku, Matthew
    Marks, Reinhard
    Kim, Kibum
    Zinzani, Pier Luigi
    Trotman, Judith
    Huang, Dan
    Waltl, Eva E.
    Winderlich, Mark
    Ambarkhane, Sumeet
    Hess, Georg
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S392 - S393
  • [36] First-Line Treatment With Subcutaneous Epcoritamab plus R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update
    Falchi, Lorenzo
    Offner, Fritz
    Belada, David
    Brody, Joshua
    Linton, Kim M.
    Karimi, Yasmin
    Cordoba, Raul
    Snauwaert, Sylvia
    Abbas, Aqeel
    Wang, Liwei
    Wu, Jun
    Elliott, Brian
    Clausen, Michael Roost
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S380 - S380
  • [37] Minimal residual disease (MRD) status by peripheral blood mononuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed/refractory follicular lymphoma (R/R FL) treated with subcutaneous (SC) epcoritamab monotherapy in the pivotal phase 1/2 EPCORE™ NHL-1 trial
    Soong, David
    Altintas, Isil
    Karavitis, John
    Linton, Kim M.
    Jurczak, Wojciech
    Thieblemont, Catherine
    Zhao, Kevin
    Szafer-Glusman, Edith
    Hoehn, Daniela
    Favaro, Elena
    Sacchi, Mariana
    Jure-Kunkel, Maria
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    McMillan, Andrew K.
    Kim, Tae Min
    Kim, Won Seog
    Hertzberg, Mark
    Ozcan, Muhit
    Penuel, Elicia
    Cheng, Ji
    Hirata, Jamie M.
    Ku, Grace
    Flowers, Christopher
    BLOOD, 2017, 130
  • [39] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
    Hainsworth, J. D.
    Arrowsmith, E. R.
    Mccleod, M.
    Fayad, L. E.
    Hamid, O.
    Davis, L.
    Lin, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
  • [40] Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study
    Schuster, Michael W.
    Canales, Miguel A.
    Westin, Jason
    Zijlstra, Josee M.
    Follows, George A.
    Karmali, Reem
    Kalakonda, Nagesh
    Goy, Andre H.
    Casasnovas, Rene-Olivier
    Vermaat, Joost
    Van den Neste, Eric
    Choquet, Sylvain
    Thieblemont, Catherine
    Cavallo, Federica
    De La Cruz, Maria de Fatima
    Hill, Brian T.
    Tilly, Herve
    Kassam, Shireen
    Bouabdallah, Reda
    Jaeger, Ulrich
    Gurion, Ronit
    Caimi, Paolo
    Martin, Peter
    Davies, Andrew
    Smith, Sonali M.
    Collins, Graham P.
    Offner, Fritz C.
    Salles, Gilles
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita A.
    Chamoun, Kamal
    Wang, Hongwei
    Shah, Jatin J.
    Shacham, Sharon
    Kauffman, Michael G.
    Maerevoet, Marie
    BLOOD, 2020, 136
12345